{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,8,31]],"date-time":"2026-08-31T10:54:22Z","timestamp":1788173662434,"version":"build-2803163510"},"reference-count":37,"publisher":"Springer Science and Business Media LLC","issue":"6","license":[{"start":{"date-parts":[[2018,8,4]],"date-time":"2018-08-04T00:00:00Z","timestamp":1533340800000},"content-version":"tdm","delay-in-days":0,"URL":"http:\/\/www.springer.com\/tdm"}],"content-domain":{"domain":["link.springer.com"],"crossmark-restriction":false},"short-container-title":["Int J Hematol"],"published-print":{"date-parts":[[2018,12]]},"DOI":"10.1007\/s12185-018-2511-6","type":"journal-article","created":{"date-parts":[[2018,8,4]],"date-time":"2018-08-04T09:58:19Z","timestamp":1533376699000},"page":"640-646","update-policy":"https:\/\/doi.org\/10.1007\/springer_crossmark_policy","source":"Crossref","is-referenced-by-count":14,"title":["Chronic myelogenous leukemia presenting with central nervous system infiltration, successfully treated with central nervous system-directed chemotherapy followed by allogeneic stem cell transplantation"],"prefix":"10.1007","volume":"108","author":[{"given":"Akira","family":"Chiba","sequence":"first","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Takashi","family":"Toya","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Hideaki","family":"Mizuno","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Junji","family":"Tokushige","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Fumihiko","family":"Nakamura","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Kumi","family":"Nakazaki","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Mineo","family":"Kurokawa","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"297","published-online":{"date-parts":[[2018,8,4]]},"reference":[{"issue":"5","key":"2511_CR1","doi-asserted-by":"publisher","first-page":"591","DOI":"10.1007\/s12185-017-2330-1","volume":"106","author":"N Usui","year":"2017","unstructured":"Usui N. JSH guideline for tumors of hematopoietic and lymphoid tissues-leukemia: 4. Chronic myelogenous leukemia (CML) \/myeloproliferative neoplasms (MPN). Int J Hematol. 2017;106(5):591\u2013611.","journal-title":"Int J Hematol"},{"issue":"Suppl 2","key":"2511_CR2","doi-asserted-by":"publisher","first-page":"159","DOI":"10.1007\/s00277-015-2324-0","volume":"94","author":"S Saussele","year":"2015","unstructured":"Saussele S, Silver RT. Management of chronic myeloid leukemia in blast crisis. Ann Hematol. 2015;94(Suppl 2):159\u201365.","journal-title":"Ann Hematol"},{"issue":"2","key":"2511_CR3","doi-asserted-by":"publisher","first-page":"167","DOI":"10.1007\/s12185-008-0032-4","volume":"87","author":"Y Wang","year":"2008","unstructured":"Wang Y, Wu D, Sun A, Jin Z, Qiu H, Miao M, et al. Allogeneic hematopoietic stem cell transplantation for patients with chronic myeloid leukemia in second chronic phase attained by imatinib after onset of blast crisis. Int J Hematol. 2008;87(2):167\u201371.","journal-title":"Int J Hematol"},{"key":"2511_CR4","doi-asserted-by":"publisher","first-page":"14","DOI":"10.1038\/sj.leu.2404955","volume":"22","author":"A Tefferi","year":"2008","unstructured":"Tefferi A, Vardiman JW. Classification and diagnosis of myeloproliferative neoplasms: the 2008 World Health Organization criteria and point-of-care diagnostic algorithms. Leukemia. 2008;22:14\u201322.","journal-title":"Leukemia"},{"key":"2511_CR5","doi-asserted-by":"crossref","first-page":"789","DOI":"10.1182\/blood.V63.4.789.789","volume":"63","author":"JE Sokal","year":"1984","unstructured":"Sokal JE, Cox EB, Baccarani M, Tura S, Gomez GA, Robertson JE, et al. Prognostic discrimination in \u201cgood-risk\u201d chronic granulocytic leukemia. Blood. 1984;63:789\u201399.","journal-title":"Blood"},{"key":"2511_CR6","doi-asserted-by":"publisher","first-page":"850","DOI":"10.1093\/jnci\/90.11.850","volume":"90","author":"J Hasford","year":"1998","unstructured":"Hasford J, Pfirrmann M, Hehlmann R, Allan NC, Baccarani M, Kluin-Nelemans JC, et al. A new prognostic score for survival of patients with chronic myeloid leukemia treated with interferon alfa. Writing Committee for the Collaborative CML Prognostic Factors Project Group. J Natl Cancer Inst. 1998;90:850\u20138.","journal-title":"J Natl Cancer Inst"},{"key":"2511_CR7","doi-asserted-by":"publisher","first-page":"282","DOI":"10.1002\/ajh.23624","volume":"89","author":"O Benjamini","year":"2014","unstructured":"Benjamini O, Dumlao TL, Kantarjian H, O\u2019Brien S, Garcia-Manero G, Faderl S, et al. Phase II trial of hyper CVAD and dasatinib in patients with relapsed Philadelphia chromosome positive acute lymphoblastic leukemia or blast phase chronic myeloid leukemia. Am J Hematol. 2014;89:282\u20137.","journal-title":"Am J Hematol"},{"key":"2511_CR8","doi-asserted-by":"publisher","first-page":"2070","DOI":"10.1182\/blood-2009-12-261586","volume":"116","author":"F Ravandi","year":"2010","unstructured":"Ravandi F, O\u2019Brien S, Thomas D, Faderl S, Jones D, Garris R, et al. First report of phase 2 study of dasatinib with hyper-CVAD for the frontline treatment of patients with Philadelphia chromosome-positive (Ph+) acute lymphoblastic leukemia. Blood. 2010;116:2070\u20137.","journal-title":"Blood"},{"issue":"13","key":"2511_CR9","first-page":"4674","volume":"9","author":"H Pfeifer","year":"2003","unstructured":"Pfeifer H, Wassmann B, Hofmann WK, Komor M, Scheuring U, Bruck P, et al. Risk and prognosis of central nervous system leukemia in patients with Philadelphia chromosome-positive acute leukemias treated with imatinib mesylate. Clin Cancer Res. 2003;9(13):4674\u201381.","journal-title":"Clin Cancer Res"},{"key":"2511_CR10","doi-asserted-by":"publisher","first-page":"179","DOI":"10.1002\/hon.737","volume":"22","author":"S Rajappa","year":"2004","unstructured":"Rajappa S, Uppin SG, Raghunadharao D, Rao IS, Surath A. Isolated central nervous system blast crisis in chronic myeloid leukaemia. Haematol Oncol. 2004;22:179\u201381.","journal-title":"Haematol Oncol"},{"issue":"8","key":"2511_CR11","doi-asserted-by":"publisher","first-page":"1623","DOI":"10.1080\/10428190410001667703","volume":"45","author":"ME Rytting","year":"2004","unstructured":"Rytting ME, Wierda WG. Central nervous system relapse in two patients with chronic myelogenous leukemia in myeloid blastic phase on imatinib mesylate therapy. Leuk Lymphoma. 2004;45(8):1623\u20136.","journal-title":"Leuk Lymphoma"},{"issue":"4","key":"2511_CR12","doi-asserted-by":"publisher","first-page":"629","DOI":"10.1080\/10428190400025120","volume":"46","author":"NA Johnson","year":"2005","unstructured":"Johnson NA, Fetni R, Caplan SN. Isolated central nervous system relapse in patients with chronic myeloid leukemia on imatinib mesylate. Leuk Lymphoma. 2005;46(4):629\u201330.","journal-title":"Leuk Lymphoma"},{"issue":"1","key":"2511_CR13","doi-asserted-by":"publisher","first-page":"79","DOI":"10.1002\/ajh.20274","volume":"79","author":"Y Beyazit","year":"2005","unstructured":"Beyazit Y, Aksu S, Kekilli M, Haznedaroglu IC, Kilickap S, Goker H. Unusual extramedullary relapses under imatinib mesylate treatment in chronic myeloid leukemia. Am J Hematol. 2005;79(1):79\u201380.","journal-title":"Am J Hematol"},{"key":"2511_CR14","doi-asserted-by":"publisher","first-page":"307","DOI":"10.1532\/IJH97.04188","volume":"81","author":"M Matsuda","year":"2005","unstructured":"Matsuda M, Morita Y, Shimada T, Miyake J, Hirase C, Tanaka M, et al. Extramedullary blast crisis derived from 2 different clones in the central nervous system and neck during complete cytogenetic response of chronic myelogenous leukemia treated with imatinib mesylate. Int J Hematol. 2005;81:307\u20139.","journal-title":"Int J Hematol"},{"key":"2511_CR15","doi-asserted-by":"publisher","first-page":"4028","DOI":"10.1200\/JCO.2006.05.5608","volume":"24","author":"HJ Kim","year":"2006","unstructured":"Kim HJ, Jung CW, Kim K, Ahn JS, Kim WS, Park K, et al. Isolated blast crisis in XNS in a patient with chronic myelogenous leukaemia maintaining major cytogenetic response after imatinib. J Clin Oncol. 2006;24:4028\u20139.","journal-title":"J Clin Oncol"},{"issue":"10","key":"2511_CR16","doi-asserted-by":"publisher","first-page":"1100","DOI":"10.1016\/j.bbmt.2008.07.002","volume":"14","author":"K Oshima","year":"2008","unstructured":"Oshima K, Kanda Y, Yamashita T, Takahashi S, Mori T, Nakaseko C, et al. Central Nervous System Relapse of Leukemia after Allogeneic Hematopoietic Stem Cell Transplantation. Biol Blood Marrow Transplant. 2008;14(10):1100\u20137.","journal-title":"Biol Blood Marrow Transplant"},{"issue":"6","key":"2511_CR17","doi-asserted-by":"publisher","first-page":"408","DOI":"10.1111\/j.1445-5994.2009.01947.x","volume":"39","author":"Y Isobe","year":"2009","unstructured":"Isobe Y, Sugimoto K, Masuda A, Hamano Y, Oshimi K. Central nervous system is a sanctuary site for chronic myelogenous leukaemia treated with imatinib mesylate. Intern Med J. 2009;39(6):408\u201311.","journal-title":"Intern Med J"},{"issue":"4","key":"2511_CR18","doi-asserted-by":"publisher","first-page":"113","DOI":"10.1016\/j.leukres.2009.09.022","volume":"34","author":"A Thomas","year":"2010","unstructured":"Thomas A, Stein CK, Gentile TC, Shah CM. Isolated CNS relapse of CML after bone marrow transplantation. Leuk Res. 2010;34(4):113\u20134.","journal-title":"Leuk Res"},{"issue":"3","key":"2511_CR19","doi-asserted-by":"publisher","first-page":"327","DOI":"10.1111\/j.1365-2141.2008.07136.x","volume":"142","author":"A Barlow","year":"2008","unstructured":"Barlow A, Robertson M, Doig A, Stewart W, Drummond MW. Isolated central nervous system lymphoid blast crisis in chronic myeloid leukaemia in major molecular remission. Br J Haematol. 2008;142(3):327.","journal-title":"Br J Haematol"},{"issue":"8","key":"2511_CR20","doi-asserted-by":"publisher","first-page":"911","DOI":"10.1007\/s00277-011-1171-x","volume":"90","author":"M Neumann","year":"2011","unstructured":"Neumann M, Blau IW, Burmeister T, Tiwtze-Buerger C, Blau O, Gerbitz A, et al. Intrathecal application of donor lymphocytes in leukemic meningeosis after allogeneic stem cell transplantation. Ann Hematol. 2011;90(8):911\u20136.","journal-title":"Ann Hematol"},{"issue":"1","key":"2511_CR21","doi-asserted-by":"publisher","first-page":"51","DOI":"10.1007\/s12288-011-0055-5","volume":"27","author":"N Radhika","year":"2011","unstructured":"Radhika N, Minakshi M, Rajesh M, Manas BR, Deepak Kumar M. Central nervous system blast crisis in chronic myeloid leukemia on imatinib mesylate therapy: report of two cases. Indian J Hematol Blood Transfus. 2011;27(1):51\u20134.","journal-title":"Indian J Hematol Blood Transfus"},{"key":"2511_CR22","doi-asserted-by":"publisher","first-page":"2","DOI":"10.1186\/1471-2326-12-9","volume":"12","author":"M Fuchs","year":"2012","unstructured":"Fuchs M, Reinh\u00f6fer M, Ragoschke-Schumm A, Sayer HG, Boer K, Witte OW, et al. Isolated central nervous system relapse of chronic myeloid leukemia after allogeneic hematopoietic stem cell transplantation. BMC Blood Disord. 2012;12:2\u20135.","journal-title":"BMC Blood Disord"},{"issue":"11","key":"2511_CR23","doi-asserted-by":"publisher","first-page":"745","DOI":"10.6004\/jnccn.2013.0097","volume":"11","author":"SM Lindhorst","year":"2013","unstructured":"Lindhorst SM, Lopez RD, Sanders RD. An unusual presentation of chronic myelogenous leukemia: a review of isolated central nervous system relapse. J Natl Compr Cancer Netw. 2013;11(11):745\u201350.","journal-title":"J Natl Compr Cancer Netw"},{"key":"2511_CR24","doi-asserted-by":"publisher","first-page":"111","DOI":"10.1159\/000347158","volume":"130","author":"M Nishimoto","year":"2013","unstructured":"Nishimoto M, Nakamae H, Koh KR, Kosaka S, Matsumoto K, Morita K, et al. Dasatinib maintenance therapy after allogeneic hematopoietic stem cell transplantation for an isolated central nervous system blast crisis in chronic myelogenous leukemia. Acta Haematol. 2013;130:111\u20134.","journal-title":"Acta Haematol"},{"key":"2511_CR25","first-page":"1149","volume":"28","author":"S Gaur","year":"2014","unstructured":"Gaur S, Torabi AR, Corral J. Isolated central nervous system relapse in two patients with BCR-ABL-positive acute leukemia while receiving a next-generation tyrosine kinase inhibitor. In Vivo. 2014;28:1149\u201353.","journal-title":"In Vivo"},{"key":"2511_CR26","doi-asserted-by":"publisher","first-page":"247","DOI":"10.3343\/alm.2014.34.3.247","volume":"34","author":"MJ Park","year":"2014","unstructured":"Park MJ, Park PW, Seo YH, Kim KH, Seo JY, Jeong JH, et al. A case of isolated lymphoblastic relapse of the central nervous system in a patient with chronic myelogenous leukemia treated with imatinib. Ann Lab Med. 2014;34:247\u201351.","journal-title":"Ann Lab Med"},{"key":"2511_CR27","doi-asserted-by":"publisher","first-page":"1957","DOI":"10.3892\/ol.2015.2928","volume":"9","author":"SW Lai","year":"2015","unstructured":"Lai SW, Huang TC, Chen JH, Wu YY, Chang PY. Dasatinib as the salvage therapy for chronic myeloid leukemia with blast crisis and central nervous system involvement: a case report. Oncol Lett. 2015;9:1957\u201361.","journal-title":"Oncol Lett"},{"key":"2511_CR28","first-page":"1460","volume":"8","author":"Z Xu","year":"2015","unstructured":"Xu Z, Zheng M, Wu C, Ma Y, Meng L, Zhou J, et al. The overwhelmingly positive response to Dasatinib of a patient with multiple blast crisis of chronic myeloid leukemia. Int J Clin Exp Med. 2015;8:1460\u20136.","journal-title":"Int J Clin Exp Med"},{"key":"2511_CR29","doi-asserted-by":"publisher","first-page":"232915","DOI":"10.1155\/2015\/232915","volume":"2015","author":"J Gomez","year":"2015","unstructured":"Gomez J, Duenas V. Isolated central nervous system relapse in chronic myeloid leukemia. Case Rep Med. 2015;2015:232915.","journal-title":"Case Rep Med"},{"key":"2511_CR30","first-page":"OE01","volume":"10","author":"A Jain","year":"2016","unstructured":"Jain A, Gupta N. Isolated CNS blast crises in chronic myeloid leukaemia presenting as hypertrophic pachymeningitis and bilateral optic neuritis: a case report. J Clin Diagn Res. 2016;10:OE01\u20135.","journal-title":"J Clin Diagn Res"},{"issue":"4","key":"2511_CR31","doi-asserted-by":"publisher","first-page":"695","DOI":"10.1080\/10428190310001625728","volume":"45","author":"JF Leis","year":"2004","unstructured":"Leis JF, Stepan DE, Curtin PT, Ford JM, Peng B, Schubach S, et al. Central nervous system failure in patients with chronic myelogenous leukemia lymphoid blast crisis and Philadelphia chromosome positive acute lymphoblastic leukemia treated with imatinib (STI-571). Leuk Lymphoma. 2004;45(4):695\u20138.","journal-title":"Leuk Lymphoma"},{"issue":"2","key":"2511_CR32","doi-asserted-by":"publisher","first-page":"695","DOI":"10.1073\/pnas.86.2.695","volume":"86","author":"C Cordon-Cargo","year":"1989","unstructured":"Cordon-Cargo C, O\u2019Brien JP, Casals D, Rittman-Grauer L, Biedler JL, Melamed MR, et al. Multidrug-resistance gene (P-glycoprotein) is expressed by endothelial cells at blood-brain barrier sites. Proc Natl Acad Sci USA. 1989;86(2):695\u20138.","journal-title":"Proc Natl Acad Sci USA"},{"key":"2511_CR33","doi-asserted-by":"publisher","first-page":"1085","DOI":"10.1124\/jpet.102.045260","volume":"304","author":"H Dai","year":"2003","unstructured":"Dai H, Marbach P, Lemaire M, Hayes M, Elmquist WF. Distribution of STI-571 to the brain is limited by P-glycoprotein mediated efflux. J Pharmacol Exp Ther. 2003;304:1085\u201392.","journal-title":"J Pharmacol Exp Ther"},{"issue":"11","key":"2511_CR34","doi-asserted-by":"publisher","first-page":"4500","DOI":"10.1158\/0008-5472.CAN-05-0259","volume":"65","author":"T O\u2019Hare","year":"2005","unstructured":"O\u2019Hare T, Walters DK, Stoffregen EP, Jia T, Manley PW, Mestan J, et al. In vitro activity of Bcr-Abl inhibitors AMN107 and BMS-354825 against clinically relevant imatinib-resistant Abl kinase domain mutants. Cancer Res. 2005;65(11):4500\u20135.","journal-title":"Cancer Res"},{"issue":"4","key":"2511_CR35","doi-asserted-by":"publisher","first-page":"1005","DOI":"10.1182\/blood-2008-02-140665","volume":"112","author":"K Porkka","year":"2008","unstructured":"Porkka K, Koskenvesa P, Lund\u00e1n T, Rimpilainen J, Mustjoki S, Smykla R, et al. Dasatinib crosses the blood-brain barrier and is an efficient therapy for central nervous system Philadelphia chromosome-positive leukemia. Blood. 2008;112(4):1005\u201312.","journal-title":"Blood"},{"key":"2511_CR36","doi-asserted-by":"publisher","first-page":"373","DOI":"10.1002\/cncr.28433","volume":"120","author":"P Strari","year":"2014","unstructured":"Strari P, Kantarjian H, Thomas D, O\u2019Brien S, Konoplev S, Jorgensen JL, et al. HCVAD plus imatinib or dasatinib in lymphoid blastic phase chronic myeloid leukemia. Cancer. 2014;120:373\u201380.","journal-title":"Cancer"},{"key":"2511_CR37","doi-asserted-by":"publisher","first-page":"1025","DOI":"10.1016\/j.hoc.2011.09.003","volume":"25","author":"N Jain","year":"2011","unstructured":"Jain N, van Besign K. Chronic myelogenous leukemia: role of stem cell transplant in the imatinib era. Hematol Oncol Clin N Am. 2011;25:1025\u201348.","journal-title":"Hematol Oncol Clin N Am"}],"container-title":["International Journal of Hematology"],"original-title":[],"language":"en","link":[{"URL":"http:\/\/link.springer.com\/article\/10.1007\/s12185-018-2511-6\/fulltext.html","content-type":"text\/html","content-version":"vor","intended-application":"text-mining"},{"URL":"http:\/\/link.springer.com\/content\/pdf\/10.1007\/s12185-018-2511-6.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"text-mining"},{"URL":"http:\/\/link.springer.com\/content\/pdf\/10.1007\/s12185-018-2511-6.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2019,10,21]],"date-time":"2019-10-21T21:11:24Z","timestamp":1571692284000},"score":1,"resource":{"primary":{"URL":"http:\/\/link.springer.com\/10.1007\/s12185-018-2511-6"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2018,8,4]]},"references-count":37,"journal-issue":{"issue":"6","published-print":{"date-parts":[[2018,12]]}},"alternative-id":["2511"],"URL":"https:\/\/doi.org\/10.1007\/s12185-018-2511-6","relation":{},"ISSN":["0925-5710","1865-3774"],"issn-type":[{"value":"0925-5710","type":"print"},{"value":"1865-3774","type":"electronic"}],"subject":[],"published":{"date-parts":[[2018,8,4]]},"assertion":[{"value":"8 May 2018","order":1,"name":"received","label":"Received","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"30 July 2018","order":2,"name":"revised","label":"Revised","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"31 July 2018","order":3,"name":"accepted","label":"Accepted","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"4 August 2018","order":4,"name":"first_online","label":"First Online","group":{"name":"ArticleHistory","label":"Article History"}},{"order":1,"name":"Ethics","group":{"name":"EthicsHeading","label":"Compliance with ethical standards"}},{"value":"M.K. received lecture fee and research grants from Bristol-Myers Squibb. M.K. received lecture fee and research grants and F.N. received lecture fee from Novartis Pharma K.K.","order":2,"name":"Ethics","group":{"name":"EthicsHeading","label":"Conflict of interest"}}]}}